Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal) - Names and Identifiers
| Name | Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal)
|
| Synonyms | Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal)
|
| CAS | 13872-18-9
|
Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal) - Upstream Downstream Industry
Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal) - Introduction
Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal) is a chemical substance, also known as ATD. The following is a description of its nature, use, formulation and safety information:
Nature:
Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal) is a white crystalline solid with formula C24H34O5. Its melting point and boiling point are 110-112°C and 444°C, respectively. The compound has high solubility in organic solvents.
Use:
ATD is an anti-androgen whose main effect is to inhibit the synthesis of male hormones such as testosterone. It is commonly used as a stimulant control agent in sports athletes and fitness enthusiasts to promote muscle growth, build strength and improve physical fitness levels.
Preparation Method:
Androst-5-ene-3,11,17-trione, Cyclic 3,17-Bis(1,2-ethanediyl acetal) can be prepared by several synthetic routes, including the synthesis of androstene compounds and aldehyde condensation polymerization.
Safety Information:
Long-term exposure and abuse of ATD may pose a risk to human health. Use should follow the prescribed dosage and recommendations for use and should be under the supervision of a doctor or professional. Like many compounds, ATD can also cause allergic reactions or other adverse reactions. Therefore, proper safety assessment and risk management should be performed prior to use.
Please note that ATD is listed as a controlled chemical substance in many countries, and illegal use and abuse can lead to legal issues. Please ensure compliance with local laws and regulations regarding use and access.
Last Update：2024-04-10 22:29:15